Guangdong Marubi Biotechnology Co (603983) Fair Value & Analysis
Consumer Defensive · CN · Market cap 8.9B CNY
Fair value as of: Jul 12, 2026
From 26 valuation models · updated 29 days ago
Share price +1.3% over the past month.
A solid business, but screening 58% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (¥15.94). The favourable scenario is already priced in.
- Solid but not exceptional quality (68/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (¥7.57 to ¥15.94) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 12, 2026.
How to read this chart
60‑month range ¥19.12 – ¥59.80 · fair‑value band ¥7.57 – ¥15.94 · the ¥30.20 price screens above the ¥12.71 fair value. Dashed = 300-day average. As of Jul 12, 2026.
Analysis
Guangdong Marubi Biotechnology Co (603983) currently trades at ¥30.20, while our model-based Fair Value estimate is ¥12.71, implying the stock looks roughly 57.9% overvalued today. The Quality Score stands at 68/100 (solid quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Guangdong Marubi Biotechnology Co generated revenue of 3.5B CNY at a net margin of 6.1%. Revenue grew 4.1% year over year. It earns a return on equity of 6.0%. The balance sheet holds a net cash position of 1.2B CNY. Fundamentals as of Jul 12, 2026
Our scenario range runs from ¥7.57 (bear case) to ¥15.94 (bull case); at ¥30.20, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 34% below its 52-week high and 42% above its 52-week low, currently below its 200-day average. For context, the median of 10 Consumer Defensive peers we cover trades at -26% fair-value upside, at -58%, 603983 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Growth Earnings (¥12.61) versus Asset-Based (¥5.57). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 12, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 66 · Market factors (momentum, volatility) 40
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Guangdong Marubi Biotechnology Co., Ltd. engages in the research and development, design, production, sale, and service of various cosmetics in China. The company offers eye care, skincare, cleansing, and beauty and other products. It sells its products under the Marubi, Lianhuo, Chunji, and Passional Lover brands.
Full company description
Guangdong Marubi Biotechnology Co., Ltd. engages in the research and development, design, production, sale, and service of various cosmetics in China. The company offers eye care, skincare, cleansing, and beauty and other products. It sells its products under the Marubi, Lianhuo, Chunji, and Passional Lover brands. The company was founded in 2002 and is based in Guangzhou, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Guangdong Marubi Biotechnology Co reported revenue of ¥3.5B in FY2025 versus ¥1.8B in FY2021, a compound +18.0%/yr. Reported net income was ¥247M in FY2025, compounding −0.1%/yr from FY2021.
603983 screens 58% overvalued. Compare with The Procter & Gamble Company →
Peer Group
Household & Personal Products · 244 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Household & Personal Products median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Household & Personal Products stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| The Procter & Gamble Company PG | $146.80 | $108.16 | -26% |
| Unilever PLC ULN | 1,080 MXN | 1,273 MXN | +18% |
| Hindustan Unilever Limited HINDUNILVR | ₹2,144 | ₹1,000 | -53% |
| Essity AB ESSITYA | kr 279.00 | kr 250.02 | -10% |
| Godrej Consumer Products Limited GODREJCP | ₹1,088 | ₹367.64 | -66% |
| Marico Limited MARICO | ₹846.75 | ₹233.05 | -72% |
| APR Co 278470 | 375,000 KRW | 151,222 KRW | -60% |
| Dabur India Limited DABUR | ₹429.45 | ₹181.60 | -58% |
| Kimberly-Clark de México, S. A. B. de C. V., KIMBERA | 38.07 MXN | 50.09 MXN | +32% |
| PT Unilever Indonesia Tbk UNVR | 1,730 IDR | 1,934 IDR | +12% |
Compare Guangdong Marubi Biotechnology Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Consumer Defensive stocks →
Frequently asked questions
Is Guangdong Marubi Biotechnology Co (603983) overvalued or undervalued?
What is the fair value of 603983?
What is the quality score of 603983?
What is the revenue of Guangdong Marubi Biotechnology Co (603983)?
What is the net profit margin of 603983?
Does Guangdong Marubi Biotechnology Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Guangdong Marubi Biotechnology Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.